ANTX - AN2 Therapeutics, Inc.

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 1.17

Open

$ 1.15

Bid

$ 1.13 x 200

Ask

$ 1.36 x 560

Day's Range

$ 1.14 - $ 1.20

52 Week Range

$ 0.98 - $ 1.68

Volume

106,312

Average Volume

Market Cap

31.97M

Beta (5Y Monthly)

$ 1.48

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-12-2025	06-30-2025	10-Q
2	05-13-2025	03-31-2025	10-Q
3	03-25-2025	12-31-2024	10-K
4	11-13-2024	09-30-2024	10-Q
5	08-13-2024	06-30-2024	10-Q
6	05-14-2024	03-31-2024	10-Q
7	03-29-2024	12-31-2023	10-K
8	11-09-2023	09-30-2023	10-Q
9	08-10-2023	06-30-2023	10-Q
10	05-11-2023	03-31-2023	10-Q
11	03-29-2023	12-31-2022	10-K
12	11-09-2022	09-30-2022	10-Q
13	08-11-2022	06-30-2022	10-Q
14	05-10-2022	03-31-2022	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

12 Health Care Stocks Moving In Tuesday's ...
09/23/2025 21:07:00

AN2 Therapeutics Q2 EPS $(0.21) Beats $(0....
08/12/2025 20:20:45

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0....

AN2 Therapeutics Completes Dosing In first...
08/12/2025 11:06:07

AN2 Therapeutics And DNDi Collaborate Anno...
07/23/2025 11:04:23

AN2 Therapeutics Completed Its 200-patient...
06/30/2025 11:11:17

Study highlights high mortality despite standard of care and provides critical data to optimize design for upcoming proof-of-co...

AN2 Therapeutics Q1 GAAP EPS $(0.35) Misse...
05/13/2025 22:01:01

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(...

JMP Securities Maintains Market Outperform...
05/05/2025 13:31:58

JMP Securities analyst Roy Buchanan maintains AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and lowers the price t...

12 Health Care Stocks Moving In Thursday's...
05/01/2025 21:06:23

AN2 Therapeutics Reports Phase 3 Portion O...
05/01/2025 20:01:39

EBO-301 truncated Phase 3 study (n=97) misses primary endpoint; results unable to confirm clinical efficacy observed in Phase 2...

Citizens Capital Markets Reiterates Market...
03/26/2025 13:07:04

Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintai...

AN2 Therapeutics Q4 2024 GAAP EPS $(0.25) ...
03/25/2025 20:06:17

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0....

Citizens Capital Markets Reiterates Market...
02/25/2025 15:32:15

Citizens Capital Markets analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintai...

AN2 Therapeutics Advances Phase 3 EBO-301 ...
02/24/2025 12:08:45

AN2 Selects QOL-B as New Phase 3 Primary Efficacy EndpointGoal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potent...

JMP Securities Reiterates Market Outperfor...
02/03/2025 13:56:17

JMP Securities analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 pric...

JMP Securities Reiterates Market Outperfor...
11/19/2024 17:35:00

JMP Securities analyst Roy Buchanan reiterates AN2 Therapeutics (NASDAQ:ANTX) with a Market Outperform and maintains $5 pric...

TD Cowen Downgrades AN2 Therapeutics to Hold
11/18/2024 13:55:07

TD Cowen analyst Ritu Baral downgrades AN2 Therapeutics (NASDAQ:ANTX) from Buy to Hold.

AN2 Therapeutics Provides Important EBO-30...
11/13/2024 21:02:32

Epetraborole-treated patients demonstrated clinical improvements in QOL-B and a post-hoc analysis of MACrO2 with nominal statis...

AN2 Therapeutics Q3 EPS $(0.43) Beats $(0....
11/13/2024 21:01:58

AN2 Therapeutics (NASDAQ:ANTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0....

AN2 Therapeutics Receives Continuation Gra...
10/17/2024 11:03:09

why-levi-strauss-shares-are-trading-lower-by-over-10-here-are-20-stocks-moving-premarket

Why Levi Strauss Shares Are Trading Lower ...
10/03/2024 09:24:16